不对称二甲基精氨酸与心血管相关疾病发病机制的研究进展  

Research progress between Asymmetric Dimethylarginine and cardiovascular disease pathogenesis

作　　者：郭紫轩 刘运洪[2] 彭传梅 王杨[1] 卫波[1] 高辉[1] 

机构地区：[1]昆明医科大学附属延安医院检验科,昆明650051 [2]中国科学院深圳先进技术研究院

出　　处：《临床心血管病杂志》2017年第8期726-730,共5页Journal of Clinical Cardiology

基　　金：云南省应用基础研究(昆医联和专项)(No:2015FB089);昆明医科大学2017年研究生创新基金(No:2017S150)

摘　　要：心血管疾病已成为我国乃至全球面临的重大疾病之一。不对称二甲基精氨酸(ADMA)是内源性一氧化氮合酶(NOs)的抑制剂,竞争抑制一氧化氮(NO)的产生,诱发氧化应激反应,引起血管内皮功能不全,导致心血管疾病的发生发展。现已发现ADMA是心血管疾病新的独立预测因子及危险因素,本文对ADMA在心血管相关疾病的调控机制,以及其作为一种新的标志物在心血管相关疾病诊断中的研究进展进行综述。Cardiovascular disease has become one of the major diseases that our country and even the whole world faces.Two asymmetric dimethylarginine（ADMA）is an endogenous nitric oxide synthase（NOs）inhibitor,competitive inhibition of nitric oxide（NO）production induced oxidative stress caused by vascular endothelial dysfunction,leading to the development of cardiovascular disease.It has been found that ADMA is the independent predictor of cardiovascular disease risk and new factors,the regulation mechanism of ADMA in cardiovascular related diseases,as well as a new marker in the diagnosis of cardiovascular disease related research progress are reviewed in this article.

关 键 词：不对称二甲基精氨酸 一氧化氮 心血管疾病 

分 类 号：R543[医药卫生—心血管疾病]